Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor reported 13 stocks worth $308M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are PCVX (26.9%), ARQT (10.8%) and TRVI (10.6%). Compared with Q1 2026, the fund opened new positions in AVLN, added to PCVX, TRVI and AVTX, trimmed ARQT, OCS and ZBIO and sold out of BOLT.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PCVX Vaxcyte Inc | $82.9M | 26.9% | 1.4M | +53K (+4%) | 8 of 8 | |
| 2 |  ARQT Arcutis Biotherapeutics Inc | $33.2M | 10.8% | 1.3M | −91K (−7%) | 8 of 8 | |
| 3 |  TRVI Trevi Therapeutics Inc | $32.5M | 10.6% | 1.7M | +189K (+12%) | 5 of 8 | |
| 4 |  AVLN Avalyn Pharma Inc | $31.8M | 10.3% | 967K | New position | 1 of 8 | |
| 5 |  EVMN Evommune Inc | $25.6M | 8.3% | 1.9M | No change | 3 of 8 | |
| 6 |  MPLT Maplight Therapeutics Inc | $21.9M | 7.1% | 611K | No change | 3 of 8 | |
| 7 |  OCS Oculis Holding AG | $20.9M | 6.8% | 1.5M | −174K (−10%) | 8 of 8 | |
| 8 |  BIOA Bioage Labs Inc | $16M | 5.2% | 653K | No change | 8 of 8 | |
| 9 |  IMNM Immunome Inc | $15.5M | 5.0% | 733K | No change | 4 of 8 | |
| 10 |  ZBIO Zenas Biopharma Inc | $12.5M | 4.0% | 491K | −101K (−17%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 BOLT Bolt Biotherapeutics Inc | $172K | 43K |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 13, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Pivotal bioVenture Partners Investment Advisor 13F FAQ
What does Pivotal bioVenture Partners Investment Advisor own?
Pivotal bioVenture Partners Investment Advisor reported 13 stocks worth $308M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are PCVX (26.9%), ARQT (10.8%) and TRVI (10.6%). The table above lists every position in the filing (the top 10 without an account).
What did Pivotal bioVenture Partners Investment Advisor buy and sell in Q2 2026?
Compared with Q1 2026: 1 new positions, 3 added to, 3 trimmed and 1 sold out. New positions include AVLN. It sold all of BOLT.
When will Pivotal bioVenture Partners Investment Advisor file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Pivotal bioVenture Partners Investment Advisor's portfolio worth?
The Q2 2026 filing reports $308M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.